Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II placebo-controlled study of VGX-3100 for HPV16/18-associated cervical intraepithelial neoplasia
2012-001334-33Phase 2Completed
- Sponsor
- Inovio Pharmaceuticals, Inc.
- Start
- Aug 2012
- Modality
- Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Prophylactic Vaccines → Vaccines & Immunotherapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial in cervical intraepithelial neoplasia (CIN), cervical dysplasia (CIN) and human papillomavirus infection comparing VGX-3100 with Placebo (2 arms). Primary endpoint: Histopathological regression of cervical lesions to CIN 1 or less. Started Aug 2012; status: completed.
02
Drugs
bizalimogene ralaplasmid
03
Conditions
cervical intraepithelial neoplasia (CIN)cervical dysplasia (CIN)human papillomavirus infection
Beyond the preview
Go deeper on 2012-001334-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-001334-33.